What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma,…
What is Indaptus Therapeutics, Inc.'s P/E and P/B ratio?
Indaptus Therapeutics, Inc. has a P/E ratio of -0.5 and a P/B ratio of 35.03.
What is Indaptus Therapeutics, Inc.'s debt-to-equity ratio?
Indaptus Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Indaptus Therapeutics, Inc. owe compared with what it owns?
Indaptus Therapeutics, Inc. owes $0.05 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Indaptus Therapeutics, Inc.'s Positivity rank?
Indaptus Therapeutics, Inc. is ranked #6,149 of 6,774 companies globally and #3,495 of 4,000 in United States on PositoAI, with a Positivity Score of 6,835.
Does Indaptus Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Indaptus Therapeutics, Inc..
Where can I read the latest news about Indaptus Therapeutics, Inc.?
Recent headlines about Indaptus Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Indaptus Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Indaptus Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.